Publication of the Breast Cancer Study Abstract to be presented at ASCO 2016

Board Intentions to apply for long-term fund-raising plan
May 13, 2016
Media reports that Michael Chang, the chairman of the company, Amy Huang, the general manager and the staffs, six people in total, were guaranteed pending summons for alleged insider trading.
May 26, 2016
1.Date of occurrence of the event:2016/05/19
2.Name of the company: OBI Pharma, Inc.
3.Relationship to the Company (please enter ”head office” or ”affiliate
company”): The Company head office
4.Reciprocal shareholding ratios:N/A
5.Name of the reporting media:N/A
6.Content of the report:N/A
7.Cause of occurrence: OBI Pharma published the abstract of OBI Pharma’s
clinical study, entitled, ”A Double-blind, Randomized Trial of Active
Immunotherapy With Globo H-KLH (OPT-822) in Subjects With Metastatic
Breast Cancer” (Abstract: Randomized Phase 2/3 Trial of Active Immunotherapy
With OPT-822/OPT-821 in Patients With Metastatic Breast Cancer) on the
website of American Society of Clinical Oncology (ASCO).
8.Countermeasures: Ensure the general public is able to easily access the full
text of the abstract at the following
URL:http://abstract.asco.org/176/AbstView_176_168513.html
Here is the link to the Chinese version of the Abstract
http://www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=72
9.Any other matters that need to be specified:None